BioMarin Pharmaceutical Inc. is an American biotechnology company that develops and commercializes therapies for people living with serious and life-threatening rare genetic diseases. Its core business centers on enzyme replacement therapies, and it was the first company to provide treatments for MPS I and phenylketonuria (PKU). It operates globally with facilities across the U.S., Europe, Asia and South America.